NCT02749825

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

A Multicenter, Randomized Clinical Investigation of Trelstar Versus Continued Therapy in Patients Receiving Lupron or Zoladex for Advanced Prostate Cancer

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Pharmatech · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study looks at Testosterone levels in patients receiving Trelstar versus those receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer by the FDA.

Detailed description

Patients who are currently receiving Lupron or Zoladex will be consented and then randomized to receive either continued treatment with the drug they have been on, or will be randomized to Trelstar for a period of 3 months. At the end of that period, testosterone and prostate serum antigen (PSA) levels will be drawn and compared to their previous levels to determine if Trelstar is as effective as the previous treatment.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Trelstar	As labeled
DRUG	Lupron	As labeled
DRUG	Zoladex	As labeled

Timeline

• Start date: 2002-09-01
• Primary completion: 2006-05-01
• Completion: 2006-07-01
• First posted: 2016-04-25
• Last updated: 2016-04-25

Locations

11 sites across 1 country: United States